Sage Therapeutics (NASDAQ:SAGE) Cut to “Sell” at StockNews.com

Sage Therapeutics (NASDAQ:SAGE) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday.

SAGE has been the topic of several other research reports. Royal Bank of Canada increased their price target on shares of Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a research note on Thursday, February 15th. Oppenheimer dropped their price target on shares of Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating on the stock in a research note on Thursday. HC Wainwright reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Wedbush reaffirmed a “neutral” rating and set a $24.00 price objective on shares of Sage Therapeutics in a report on Wednesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sage Therapeutics in a report on Thursday. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $39.28.

Sage Therapeutics Stock Up 2.3 %

Shares of SAGE traded up $0.29 during mid-day trading on Friday, hitting $13.33. 1,258,722 shares of the company’s stock were exchanged, compared to its average volume of 1,009,849. The firm has a fifty day moving average of $19.85 and a two-hundred day moving average of $20.91. Sage Therapeutics has a twelve month low of $10.92 and a twelve month high of $59.99. The stock has a market cap of $801.27 million, a price-to-earnings ratio of -1.47 and a beta of 0.86.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The company had revenue of $77.97 million for the quarter, compared to analyst estimates of $60.15 million. During the same quarter in the prior year, the business posted ($2.47) EPS. Sage Therapeutics’s quarterly revenue was up 2621.5% on a year-over-year basis. On average, equities analysts predict that Sage Therapeutics will post -6.06 earnings per share for the current year.

Institutional Investors Weigh In On Sage Therapeutics

A number of hedge funds have recently made changes to their positions in SAGE. CWM LLC increased its position in Sage Therapeutics by 274.2% in the 3rd quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 883 shares in the last quarter. KBC Group NV acquired a new stake in Sage Therapeutics in the 4th quarter valued at about $28,000. China Universal Asset Management Co. Ltd. increased its position in Sage Therapeutics by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in Sage Therapeutics in the 1st quarter valued at about $34,000. Finally, Tower Research Capital LLC TRC increased its position in Sage Therapeutics by 74.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,050 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 2,148 shares in the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.